Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph C Beyer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 13, 2010
Developmental immunotoxicology assessment of rituximab in cynomolgus monkeysAnu Vaidyanathan, Kathleen McKeever, Banmeet Anand, et al.
Retina (Philadelphia, Pa.)|November 30, 2007
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsJacques Gaudreault, David Fei, Joseph C Beyer, et al.
Toxicologic Pathology|November 19, 2013
Immunogenicity/hypersensitivity of biologicsMichael W Leach, James B Rottman, M Benjamin Hock, et al.
Nature|February 12, 2010
Chronic DLL4 blockade induces vascular neoplasmsMinhong Yan, Christopher A Callahan, Joseph C Beyer, et al.
Investigative Ophthalmology & Visual Science|December 31, 2005
Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroidIvana K Kim, Deeba Husain, Norman Michaud, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 13, 2005
Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkeyDeeba Husain, Ivana Kim, Danny Gauthier, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsAmita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic ModulationJessica A Couch, Gu Zhang, Joseph C Beyer, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 13, 2010
Developmental immunotoxicology assessment of rituximab in cynomolgus monkeysAnu Vaidyanathan, Kathleen McKeever, Banmeet Anand, et al.
Retina (Philadelphia, Pa.)|November 30, 2007
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsJacques Gaudreault, David Fei, Joseph C Beyer, et al.
Toxicologic Pathology|November 19, 2013
Immunogenicity/hypersensitivity of biologicsMichael W Leach, James B Rottman, M Benjamin Hock, et al.
Nature|February 12, 2010
Chronic DLL4 blockade induces vascular neoplasmsMinhong Yan, Christopher A Callahan, Joseph C Beyer, et al.
Investigative Ophthalmology & Visual Science|December 31, 2005
Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroidIvana K Kim, Deeba Husain, Norman Michaud, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 13, 2005
Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkeyDeeba Husain, Ivana Kim, Danny Gauthier, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumorsAmita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic ModulationJessica A Couch, Gu Zhang, Joseph C Beyer, et al.
Pageof 1